Search

Your search keyword '"Camidge, D R"' showing total 49 results

Search Constraints

Start Over You searched for: Author "Camidge, D R" Remove constraint Author: "Camidge, D R" Publication Type Academic Journals Remove constraint Publication Type: Academic Journals
49 results on '"Camidge, D R"'

Search Results

2. Repotrectinib in ROS1 Fusion-Positive Non-Small-Cell Lung Cancer.

14. Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study.

15. Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer.

16. The impact of socioeconomic status on access to cancer clinical trials.

17. The cost-effectiveness of screening lung cancer patients for targeted drug sensitivity markers.

18. Economic evaluation of fulvestrant as an extra step in the treatment sequence for ER-positive advanced breast cancer.

19. Hospital admissions and deaths relating to deliberate self-harm and accidents within 5 years of a cancer diagnosis: a national study in Scotland, UK.

20. Factors affecting the mesothelioma detection rate within national and international epidemiological studies: insights from Scottish linked cancer registry-mortality data.

21. Assessing proliferation, cell-cycle arrest and apoptotic end points in human buccal punch biopsies for use as pharmacodynamic biomarkers in drug development.

22. Plucked human hair as a tissue in which to assess pharmacodynamic end points during drug development studies.

27. MO2-15-1 [Encore] Antitumor activity of TAK-788 in NSCLC With EGFR exon 20 insertions.

28. Crizotinib in ROS1 -rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001.

29. HER2 exon 20 insertions in non-small-cell lung cancer are sensitive to the irreversible pan-HER receptor tyrosine kinase inhibitor pyrotinib.

30. Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study.

31. O1-4-2 [Encore] Brigatinib (BRG) vs Crizotinib (CRZ) in Patients (Pts) With ALK Inhibitor-Naive Advanced ALK+ NSCLC from ALTA-1L.

34. Q-TWiST analysis of survival benefits with brigatinib versus crizotinib in patients with anaplastic lymphoma kinase-positive non-small cell lung cancer based on results of the ALTA-1L trial.

35. Genetic landscape of patients with ALK-rearranged non-small-cell lung cancer (NSCLC) and response to ceritinib in ASCEND-1 study.

36. Intracranial and extracranial efficacy of lorlatinib in patients with ALK-positive non-small-cell lung cancer previously treated with second-generation ALK TKIs.

37. Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry.

39. Improved EGFR mutation detection using combined exosomal RNA and circulating tumor DNA in NSCLC patient plasma.

40. Correlation of extent of ALK FISH positivity and crizotinib efficacy in three prospective studies of ALK-positive patients with non-small-cell lung cancer.

41. Crizotinib for the treatment of patients with advanced non-small cell lung cancer.

42. Adding to the mix: fibroblast growth factor and platelet-derived growth factor receptor pathways as targets in non-small cell lung cancer.

43. Is FISH floating or still swimming in the lung cancer ocean?

47. Genetic susceptibility to tuberculosis in Africans: a genome-wide scan.

48. Docetaxel-induced radiation recall dermatitis and successful rechallenge without recurrence.

49. Cloning of Drosophila beta-adaptin and its localization on expression in mammalian cells.

Catalog

Books, media, physical & digital resources